Articles related to Internal Medicine

Oncology Medical Home (OMH) is a system of care delivery that features coordinated, efficient, accessible, and evidence-based care and includes a process for measurement of outcomes to facilitate continuous quality improvement. OMH can serve as a roadmap to guide how a practice delivers high-quality oncology care (a process of practice transformation) and support (but not define) new models of value-based reimbursement.

Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. placebo among 2,639 patients recruited between 2007 and 2012, with follow-up 10 years after treatment completion.

According to a press release from April 2021, “the FDA is working toward issuing proposed product standards within the next year to ban menthol as a characterizing flavor in cigarettes and ban all characterizing flavors (including menthol) in cigars.” Acting Commissioner Janet Woodcock, MD, said the agency had now “accumulated sufficient evidence establishing the addictiveness and harm from menthol,” which provides a “trajectory” toward ending tobacco-related disease and death.

Letermovir is a recently approved antiviral shown to decrease clinically significant cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) in a phase 3, randomized, placebo-controlled trial. Appearing in Blood, the authors make two key points: 1) Letermovir prophylaxis may be associated with decreased polyfunctional CMV-specific T-cell immunity after HCT, and 2) COMPASS is an analytical tool that can effectively measure polyfunctional CMV-specific T-cell immune responses.

Without definitive treatment, mortality from severe aplastic anemia (AA) approaches 70% at 2 years. Establishing an accurate etiology of the AA is challenging but also absolutely critical to appropriate management, especially differentiating between acquired and inherited forms of the disease. This review emphasizes the newer data on molecular (somatic and germline) findings in AA and how they are (or are not) helpful during diagnosis.

According to Daniel A. Nation, PhD, associate professor of psychological science at University of California, Irvine: “Studies of angiotensin II receptor blockers and ACE inhibitors have suggested these medicines may confer the greatest benefit to long-term cognition, while other studies have shown the benefits of calcium channel blockers and diuretics on reducing dementia risk.”